Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
公司代碼RGNT
公司名稱Regentis Biomaterials Ltd
上市日期Dec 04, 2025
CEOHazum (Eli)
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址60, Medinat Hyahudim
城市HERZLIYA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家Israel
郵編4676652
電話97246265502
網址https://www.regentis.co.il/
公司代碼RGNT
上市日期Dec 04, 2025
CEOHazum (Eli)